Experts report new guidelines for clinical trial design in patients with brain metastases

Clinical trials of new anti-cancer therapies have often excluded patients whose disease has spread to the brain or central nervous system (CNS) or, if such patients were allowed on trial, trials have often failed to clearly capture information on the drug’s effect in the brain.

Powered by WPeMatico




Comments are Closed